Mast Cells as Drivers of Disease and Therapeutic Targets

Trends in Immunology

Volumn 39, Issue 2, 2018, Pages 151-162

  Siebenhaar, Frank ^a   Redegeld, Frank A ^b   Bischoff, Stephan C ^c   Gibbs, Bernhard F ^d,e   Maurer, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF HOHENHEIM   (Germany)

^d MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^e UNIVERSITY OF OLDENBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HISTAMINE; LEUKOTRIENE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN; PROTEOGLYCAN; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; ALLERGY; BYSTANDER EFFECT; CALCIUM MOBILIZATION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; DISEASE BURDEN; HUMAN; IMMUNOMODULATION; MALIGNANT NEOPLASM; MAST CELL; MAST CELL DEGRANULATION; MASTOCYTOSIS; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; URTICARIA; ANIMAL; AUTOIMMUNE DISEASE; DEGRANULATION; HYPERSENSITIVITY; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; NEOPLASM; PROCEDURES;

ANIMALS; AUTOIMMUNE DISEASES; CELL DEGRANULATION; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; INFLAMMATION; MAST CELLS; MASTOCYTOSIS; NEOPLASMS; SIGNAL TRANSDUCTION; URTICARIA;

EID: 85035199022     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.10.005     Document Type: Review

References (118)

1. Frossi, B., et al. Rheostatic functions of mast cells in the control of innate and adaptive immune responses. Trends Immunol. 38 (2017), 648–656.
2. Bulfone-Paus, S., et al. Positive and negative signals in mast cell activation. Trends Immunol. 38 (2017), 657–667.
3. Yu, Y., et al. Non-IgE mediated mast cell activation. Eur. J. Pharmacol. 778 (2016), 33–43.
4. Tsai, M., et al. Using mast cell knock-in mice to analyze the roles of mast cells in allergic responses in vivo. Chem. Immunol. Allergy 87 (2005), 179–197.
5. Tanzola, M.B., et al. Mast cells exert effects outside the central nervous system to influence experimental allergic encephalomyelitis disease course. J. Immunol. 171 (2003), 4385–4391.
6. de Vries, V.C., Noelle, R.J., Mast cell mediators in tolerance. Curr. Opin. Immunol. 22 (2010), 643–648.
7. Zaiss, D.M., et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 38 (2013), 275–284.
8. Maurer, M., et al. The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J. Exp. Med. 188 (1998), 2343–2348.
9. Maurer, M., et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 432 (2004), 512–516.
10. Akahoshi, M., et al. Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. J. Clin. Invest. 121 (2011), 418–4191.
11. Starkl, P., et al. IgE antibodies, FcepsilonRIalpha, and IgE-mediated local anaphylaxis can limit snake venom toxicity. J. Allergy Clin. Immunol. 137 (2016), 246–257 e11.
12. Marichal, T., et al. Mast cells: potential positive and negative roles in tumor biology. Cancer Immunol. Res. 1 (2013), 269–279.
13. Metz, M., et al. Mast cells can enhance resistance to snake and honeybee venoms. Science 313 (2006), 526–530.
14. Siebenhaar, F., et al. The search for mast cell and basophil models – are we getting closer to pathophysiological relevance?. Allergy 70 (2015), 1–5.
15. Dudeck, A., et al. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 34 (2011), 973–984.
16. Muto, Y., et al. Mast cells are key mediators of cathelicidin-initiated skin inflammation in rosacea. J. Invest. Dermatol. 134 (2014), 2728–2736.
17. Nakamura, Y., et al. Critical role for mast cells in interleukin-1beta-driven skin inflammation associated with an activating mutation in the nlrp3 protein. Immunity 37 (2012), 85–95.
18. Otsuka, A., et al. Requirement of interaction between mast cells and skin dendritic cells to establish contact hypersensitivity. PLoS One, 6, 2011, e25538.
19. Ando, T., et al. Critical role for mast cell Stat5 activity in skin inflammation. Cell Rep. 6 (2014), 366–376.
20. Sulcova, J., et al. Mast cells are dispensable in a genetic mouse model of chronic dermatitis. Am. J. Pathol. 185 (2015), 1575–1587.
21. de Koning, H.D., et al. Mast-cell interleukin-1beta, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome. Br. J. Dermatol. 173 (2015), 448–456.
22. Walker, M.E., et al. New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action?. Biochim. Biophys. Acta 1822 (2012), 57–65.
23. Frossi, B., et al. Mast cells are associated with the onset and progression of celiac disease. J. Allergy Clin. Immunol. 139 (2017), 1266–1274.
24. Shi, G.P., et al. Mast cells in human and experimental cardiometabolic diseases. Nat. Rev. Cardiol. 12 (2015), 643–658.
25. Nakano, T., et al. Immunological and regenerative aspects of hepatic mast cells in liver allograft rejection and tolerance. PLoS One, 7, 2012, e37202.
26. DeBruin, E.J., et al. Mast cells in human health and disease. Methods Mol. Biol. 1220 (2015), 93–119.
27. Vieira Dos Santos, R., et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br. J. Dermatol. 162 (2010), 674–676.
28. Gauvreau, G.M., et al. Allergen-induced airway responses. Eur. Respir. J. 46 (2015), 819–831.
29. Bacon, A.S., et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J. Allergy Clin. Immunol. 106 (2000), 948–954.
30. Pickert, C.N., et al. Colonoscopic allergen provocation test with rBet v 1 in patients with pollen-associated food allergy. Allergy 67 (2012), 1308–1315.
31. Hartmann, K., et al. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. Br. J. Dermatol. 162 (2010), 185–190.
32. Gorczyza, M., et al. Patients with chronic cold urticaria may benefit from doxycycline therapy. Br. J. Dermatol. 176 (2017), 259–261.
33. Valent, P., et al. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 129 (2017), 1420–1427.
34. Tharp, M.D., et al. In vitro functional reactivities of cutaneous mast cells from patients with mastocytosis. J. Invest. Dermatol. 89 (1987), 264–268.
35. Ribatti, D., The development of human mast cells. An historical reappraisal. Exp. Cell Res. 342 (2016), 210–215.
36. Leist, M., et al. Membrane-bound stem cell factor is the major but not only driver of fibroblast-induced murine skin mast cell differentiation. Exp. Dermatol. 26 (2017), 255–262.
37. Dahlin, J.S., Hallgren, J., Mast cell progenitors: origin, development and migration to tissues. Mol. Immunol. 63 (2015), 9–17.
38. Godot, V., et al. H4 histamine receptor mediates optimal migration of mast cell precursors to CXCL12. J. Allergy Clin. Immunol. 120 (2007), 827–834.
39. Liu, W.L., Histamine H4 receptor antagonists for the treatment of inflammatory disorders. Drug Discov. Today 19 (2014), 1222–1225.
40. Honjo, A., et al. Pharmacologic inhibition of Notch signaling suppresses food antigen-induced mucosal mast cell hyperplasia. J. Allergy Clin. Immunol. 139 (2017), 987–996.
41. Sehra, S., et al. TH9 cells are required for tissue mast cell accumulation during allergic inflammation. J. Allergy Clin. Immunol. 136 (2015), 433–440 e1.
42. Zhan, M., et al. Upregulated expression of substance P (SP) and NK1R in eczema and SP-induced mast cell accumulation. Cell Biol. Toxicol. 33 (2017), 389–405.
43. Marshall, J.S., et al. The role of mast cell degranulation products in mast cell hyperplasia. I. Mechanism of action of nerve growth factor. J. Immunol. 144 (1990), 1886–1892.
44. Sugawara, K., et al. Endocannabinoids limit excessive mast cell maturation and activation in human skin. J. Allergy Clin. Immunol. 129 (2012), 726–738 e8.
45. Sugawara, K., et al. Cannabinoid receptor 1 controls human mucosal-type mast cell degranulation and maturation in situ. J. Allergy Clin. Immunol. 132 (2013), 182–193.
46. Otani, I.M., et al. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J. Allergy Clin. Immunol. 131 (2013), 1576–1582.
47. Siebenhaar, F., et al. Treatment strategies in mastocytosis. Immunol. Allergy Clin. North Am. 34 (2014), 433–447.
48. Pipkorn, U., et al. Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced weal-and-flare response and a reduction in skin mast cell numbers and histamine content. Clin. Exp. Allergy 19 (1989), 19–25.
49. Barete, S., et al. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 126 (2015), 1009–1016 quiz 1050.
50. Akin, C., Cladribine for mastocytosis: benefits and risks. Blood 126 (2015), 931–932.
51. Zitvogel, L., et al. Immunological off-target effects of imatinib. Nat. Rev. Clin. Oncol. 13 (2016), 431–446.
52. Alvarez-Twose, I., et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget 8 (2016), 68950–68963.
53. Iqbal, N., Iqbal, N., Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract., 2014, 2014, 357027.
54. Gotlib, J., et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N. Engl. J. Med. 374 (2016), 2530–2541.
55. Schneeweiss, M.A., et al. The multi-kinase inhibitor DCC-2618 inhibits proliferation and survival of neoplastic mast cells and other cell types involved in systemic mastocytosis. Blood, 128, 2016, 1965.
56. Gotlib, J., Tyrosine kinase inhibitors and therapeutic antibodies in advanced eosinophilic disorders and systemic mastocytosis. Curr. Hematol. Malig. Rep. 10 (2015), 351–361.
57. BLU-285, DCC-2618 show activity against GIST. Cancer Discov. 7 (2017), 121–122.
58. Migalovich-Sheikhet, H., et al. Novel identified receptors on mast cells. Front. Immunol., 3, 2012, 238.
59. Kiwamoto, T., et al. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol. Ther. 135 (2012), 327–336.
60. Zhang, T., et al. Mast cell stabilisers. Eur. J. Pharmacol. 778 (2016), 158–168.
61. Harvima, I.T., et al. Molecular targets on mast cells and basophils for novel therapies. J. Allergy Clin. Immunol. 134 (2014), 530–544.
62. Reber, L.L., Frossard, N., Targeting mast cells in inflammatory diseases. Pharmacol. Ther. 142 (2014), 416–435.
63. Maurer, M., et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 368 (2013), 924–935.
64. Zhao, Z.T., et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J. Allergy Clin. Immunol. 137 (2016), 1742–1750 e4.
65. Eggel, A., et al. Accelerated dissociation of IgE-FcepsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. J. Allergy Clin. Immunol. 133 (2014), 1709–1719 e8.
66. Klein, O., et al. Identification of Biological and pharmaceutical mast cell- and basophil-related targets. Scand. J. Immunol. 83 (2016), 465–472.
67. Stenton, G.R., et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. Br. J. Pharmacol. 168 (2013), 1519–1529.
68. Leaker, B.R., et al. The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. Clin. Exp. Allergy 44 (2014), 1146–1153.
69. Horak, F., et al. Randomized phase 1 study of the phosphatidylinositol 3-kinase delta inhibitor idelalisib in patients with allergic rhinitis. J. Allergy Clin. Immunol. 137 (2016), 1733–1741.
70. Price, M.M., et al. A specific sphingosine kinase 1 inhibitor attenuates airway hyperresponsiveness and inflammation in a mast cell-dependent murine model of allergic asthma. J. Allergy Clin. Immunol. 131 (2013), 501–511.e1.
71. Harrison, C.A., et al. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br. J. Pharmacol. 150 (2007), 509–518.
72. Gibbs, B.F., et al. Highly specific targeting of human leukocytes using gold nanoparticle-based biologically active conjugates. J. Biomed. Nanotechnol. 10 (2014), 1259–1266.
73. Ryan, J.J., et al. Fullerene nanomaterials inhibit the allergic response. J. Immunol. 179 (2007), 665–672.
74. Wernersson, S., Pejler, G., Mast cell secretory granules: armed for battle. Nat. Rev. Immunol. 14 (2014), 478–494.
75. Moon, T.C., et al. Mast cell mediators: their differential release and the secretory pathways involved. Front. Immunol., 5, 2014, 569.
76. Caughey, G.H., Mast cell proteases as pharmacological targets. Eur. J. Pharmacol. 778 (2016), 44–55.
77. Takai, S., Jin, D., Improvement of cardiovascular remodelling by chymase inhibitor. Clin. Exp. Pharmacol. Physiol. 43 (2016), 387–393.
78. Mullol, J., et al. Update on rupatadine in the management of allergic disorders. Allergy 70 (2015), 1–24.
79. Procopiou, P.A., et al. The discovery of quinoline based single-ligand human H1 and H3 receptor antagonists. Bioorg. Med. Chem. Lett. 26 (2016), 5855–5859.
80. Finn, D.F., Walsh, J.J., Twenty-first century mast cell stabilizers. Br. J. Pharmacol. 170 (2013), 23–37.
81. Mochly-Rosen, D., et al. Protein kinase C, an elusive therapeutic target?. Nat. Rev. Drug Discov. 11 (2012), 937–957.
82. Akinleye, A., et al. Ibrutinib and novel BTK inhibitors in clinical development. J. Hematol. Oncol., 6, 2013, 59.
83. Busse, W., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108 (2001), 184–190.
84. Eggel, A., et al. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 66 (2011), 961–968.
85. Cruse, G., et al. Exon skipping of FcepsilonRIbeta eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 14115–14120.
86. Norman, P., Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin. Investig. Drugs 23 (2014), 55–66.
87. Chan, H.C., Ng, S.C., Emerging biologics in inflammatory bowel disease. J. Gastroenterol. 52 (2017), 141–150.
88. Elyoussfi, S., et al. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol. Int. 36 (2016), 603–612.
89. Rider, P., et al. Biologics for targeting inflammatory cytokines, clinical uses, and limitations. Int. J. Cell Biol., 2016, 2016, 9259646.
90. Ungar, B., Kopylov, U., Advances in the development of new biologics in inflammatory bowel disease. Ann. Gastroenterol. 29 (2016), 243–248.
91. de Garavilla, L., et al. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J. Biol. Chem. 280 (2005), 18001–18007.
92. Maryanoff, B.E., et al. Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am. J. Respir. Crit. Care Med. 181 (2010), 247–253.
93. Barrington, R., et al. The role of complement in inflammation and adaptive immunity. Immunol. Rev. 180 (2001), 5–15.
94. Gaudenzio, N., et al. Different activation signals induce distinct mast cell degranulation strategies. J. Clin. Invest. 126 (2016), 3981–3998.
95. Rojas, C., Slusher, B.S., Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: rolapitant and NEPA (netupitant/palonosetron). Cancer Treat. Rev. 41 (2015), 904–913.
96. Ali, H., Mas-related G protein coupled receptor-X2: a potential new target for modulating mast cell-mediated allergic and inflammatory diseases. J. Immunobiol., 1, 2016, 115.
97. McNeil, B.D., et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519 (2015), 237–241.
98. Subramanian, H., et al. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. J. Allergy Clin. Immunol. 138 (2016), 700–710.
99. Thurmond, R.L., The histamine H4 receptor: from orphan to the clinic. Front. Pharmacol., 6, 2015, 65.
100. Enoksson, M., et al. Mast cells as sensors of cell injury through IL-33 recognition. J. Immunol. 186 (2011), 2523–2528.
101. Komai-Koma, M., et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naive mice. Allergy 67 (2012), 1118–1126.
102. Saluja, R., et al. Interleukin-33 promotes the proliferation of mouse mast cells through ST2/MyD88 and p38 MAPK-dependent and Kit-independent pathways. J. Biol. Regul. Homeost. Agents 28 (2014), 575–585.
103. Kritas, S.K., et al. Neuropeptide NGF mediates neuro-immune response and inflammation through mast cell activation. J. Biol. Regul. Homeost. Agents 28 (2014), 177–181.
104. Skaper, S.D., Nerve growth factor: a neuroimmune crosstalk mediator for all seasons. Immunology 151 (2017), 1–15.
105. Redegeld, F.A., et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat. Med. 8 (2002), 694–701.
106. Schouten, B., et al. Contribution of IgE and immunoglobulin free light chain in the allergic reaction to cow's milk proteins. J. Allergy Clin. Immunol. 125 (2010), 1308–1314.
107. van Houwelingen, A.H., et al. Topical application of F991, an immunoglobulin free light chain antagonist, prevents development of contact sensitivity in mice. Clin. Exp. Allergy 37 (2007), 270–275.
108. Halova, I., Draber, P., Tetraspanins and transmembrane adaptor proteins as plasma membrane organizers-mast cell case. Front. Cell Dev. Biol, 4, 2016, 43.
109. Kraft, S., et al. The tetraspanin CD63 is required for efficient IgE-mediated mast cell degranulation and anaphylaxis. J. Immunol. 191 (2013), 2871–2878.
110. Bochner, B.S., “Siglec”ting the allergic response for therapeutic targeting. Glycobiology 26 (2016), 546–552.
111. Gauvreau, G.M., et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J. Allergy Clin. Immunol. 138 (2017), 1051–1059.
112. Kocatürk, E., et al. Looking forward to new targeted treatments for chronic spontaneous urticaria, Clin. Transl. Allergy, 10(7), 2017, 1, 10.1186/s13601-016-0139-2.
113. Lortholary, O., et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet 389 (2017), 612–620.
114. Evans, E.K., et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci. Transl. Med., 2017, 9.
115. Gotlib, J., et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N. Engl. J. Med. 374 (2016), 2530–2541.
116. Alvarez-Twose, I., et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget 8 (2016), 68950–68963.
117. Hochhaus, A., et al. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J. Cancer Res. Clin. Oncol. 141 (2015), 2047–2060.
118. Jin, B., et al. Ponatinib induces apoptosis in imatinib-resistant human mast cells by dephosphorylating mutant D816V KIT and silencing β-catenin signaling. Mol. Cancer Ther. 13 (2014), 1217–1230.